Agency Business briefs

Share this article:

Siren Interactive, a shop focused on rare disorder therapies, became the first CRM firm to credential its staff in regulatory compliance for internet marketing and social media through the Center for Communication Compliance and the Word of Mouth Marketing Association. 

Dudnyk named Lynn Paolicelli, RN VP director of digital strategy. She joins the firm from Blue Diesel, where she was VP, account director. 

Centron landed the medical communications assignment for OraPharma's Arestin, a localized antibiotic used in periodontics. It's a new client for the New York-based HealthStar shop. 

Ogilvy Washington won a five-year, multi-million dollar contract from the National Heart, Lung and Blood Institute for The Heart Truth Campaign. It's aimed at educating women about heart disease and features an iconic red dress. 

Flaum Partners has rebranded as the Flaum Ideas Group. The New York-based healthcare marketing consultancy was launched in 2004 by CEO Sander Flaum after leading Euro RSCG Life's Robert A. Becker Agency, which became part of Euro RSCG Life Chelsea.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?